GlassScriptPhysician profile
Scott R Reiter
NPI 1316980543
$2,899.66
in general payments reported to CMS, 2019-2025
29 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $255 · 2021: $316 · 2022: $318 · 2023: $478 · 2024: $469 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $915.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $235.14 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $196.52 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $176.75 | 2019-2024 | |
| Exact Sciences Corporation | $142.52 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $142.06 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $125.60 | 2025 | Auvelity |
| Pfizer INC. | $117.73 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $109.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.64 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $75.35 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $71.88 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $67.18 | 2021-2022 | |
| Radius Health, INC. | $66.14 | 2024-2025 | Tymlos |
| Amarin Pharma, INC. | $53.02 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $50.36 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $39.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $27.71 | 2019 | |
| Allergan, INC. | $26.44 | 2020 | |
| Ascensia Diabetes Care US INC. | $25.35 | 2025 | |
| Inspire Medical Systems, INC. | $24.95 | 2025 | Inspire |
| Averitas Pharma INC. | $20.91 | 2025 | Qutenza |
| Resmed Corp | $19.52 | 2024 | |
| Abbott Laboratories | $18.37 | 2021 | |
| Dexcom, INC. | $16.92 | 2022 | |
| Horizon Therapeutics Plc | $15.92 | 2019 | |
| Corcept Therapeutics | $14.90 | 2019 | |
| Philips North America LLC | $14.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Reiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.